,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2013', 'fs': 'Sep 2013', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvCUAU'}, 'Id': 'a0P2P000005jLvCUAU', 'Event_Date__c': '2013-09-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Sep 2013', 'Status_History__c': 'a132P000000AqSgQAK'}, 'change': None}]",Sep 2013,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvDUAU'}, 'Id': 'a0P2P000005jLvDUAU', 'Event_Date__c': '2013-11-06', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqXDQA0'}, 'change': None}, {'Summary': {'s': 'The Committee also recommended the application be referred to the Gastro-intestinal Subcommittee for further advice, including advice on the appropriate scoring scale for assessing disease severity.', 'fs': 'The Committee also recommended the application be referred to the Gastro-intestinal Subcommittee for further advice, including advice on the appropriate scoring scale for assessing disease severity.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 November 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 November 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvEUAU'}, 'Id': 'a0P2P000005jLvEUAU', 'Event_Date__c': '2013-11-07', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 November 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Committee also recommended the application be referred to the Gastro-intestinal Subcommittee for further advice, including advice on the appropriate scoring scale for assessing disease severity.', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqWrQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvHUAU'}, 'Id': 'a0P2P000005jLvHUAU', 'Event_Date__c': '2014-05-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqemQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2014-05-21.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2014-05-21.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Wednesday 21 May 2014.', 'fs': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Wednesday 21 May 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvIUAU'}, 'Id': 'a0P2P000005jLvIUAU', 'Event_Date__c': '2014-05-21', 'Event_Description__c': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Wednesday 21 May 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2014-05-21.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'May 2014', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000AqhDQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2014', 'fs': 'Nov 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvJUAU'}, 'Id': 'a0P2P000005jLvJUAU', 'Event_Date__c': '2014-11-06', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 6 November 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Nov 2014', 'Status_History__c': 'a132P000000Aqp2QAC'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that adalimumab be funded as a second-line biologic therapy only for patients who were secondary non-responders to infliximab with a high priority.    The Subcommittee also recommended that adalimumab as first-line biologic therapy in the treatment of moderate to severe ulcerative colitis be declined.', 'fs': 'The Subcommittee recommended that adalimumab be funded as a second-line biologic therapy only for patients who were secondary non-responders to infliximab with a high priority.    The Subcommittee also recommended that adalimumab as first-line biologic therapy in the treatment of moderate to severe ulcerative colitis be declined.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2017-4.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2017-4.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2017', 'fs': 'Mar 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Tuesday 28 March 2017.', 'fs': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Tuesday 28 March 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvMUAU'}, 'Id': 'a0P2P000005jLvMUAU', 'Event_Date__c': '2017-03-28', 'Event_Description__c': 'Clinical advice received from Gastrointestinal Subcommittee at meeting Tuesday 28 March 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2017-4.pdf"" target=""_blank"">Gastrointestinal Subcommittee minutes</a></p>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee recommended that adalimumab be funded as a second-line biologic therapy only for patients who were secondary non-responders to infliximab with a high priority.    The Subcommittee also recommended that adalimumab as first-line biologic therapy in the treatment of moderate to severe ulcerative colitis be declined.', 'Formatted_Date__c': 'Mar 2017', 'Status_History__c': 'a132P000000ArGnQAK'}, 'change': None}, {'Summary': {'s': 'PTAC noted the Subcommittee&#39;s recommendations on adalimumab for ulcerative colitis, but considered that this was a large patient group and potentially high budget risk. PTAC requested to review the evidence in support of the Subcommittee&#39;s recommendation.', 'fs': 'PTAC noted the Subcommittee&#39;s recommendations on adalimumab for ulcerative colitis, but considered that this was a large patient group and potentially high budget risk. PTAC requested to review the evidence in support of the Subcommittee&#39;s recommendation.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2017', 'fs': 'Nov 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 November 2017.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 November 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvNUAU'}, 'Id': 'a0P2P000005jLvNUAU', 'Event_Date__c': '2017-11-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 November 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'PTAC noted the Subcommittee&#39;s recommendations on adalimumab for ulcerative colitis, but considered that this was a large patient group and potentially high budget risk. PTAC requested to review the evidence in support of the Subcommittee&#39;s recommendation.', 'Formatted_Date__c': 'Nov 2017', 'Status_History__c': 'a132P000000ArMeQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2018', 'fs': 'May 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 3 May 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 3 May 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvOUAU'}, 'Id': 'a0P2P000005jLvOUAU', 'Event_Date__c': '2018-05-03', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 3 May 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'May 2018', 'Status_History__c': 'a132P000000ArSGQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2018', 'fs': 'May 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvPUAU'}, 'Id': 'a0P2P000005jLvPUAU', 'Event_Date__c': '2018-05-26', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2018', 'Status_History__c': 'a132P000000ArTAQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2019', 'fs': 'Nov 2019', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvQUAU'}, 'Id': 'a0P2P000005jLvQUAU', 'Event_Date__c': '2019-11-28', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2019', 'Status_History__c': 'a132P000000BBbzQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that <span style=""color: black;"">adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis (UC) </span>be funded with a low priority subject to the following Special Authority criteria:</p><p><span style=""font-size: 9pt;"">ADALIMUMAB</span></p><p><b style=""font-size: 9pt;"">Initial application – (moderate to severely active ulcerative colitis; first biologic line)</b></p><p><span style=""font-size: 9pt;"">Only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has histologically confirmed ulcerative colitis that is moderate to severely active; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) score is greater than or equal to 4; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and systemic corticosteroids; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Surgery (or further surgery) is considered to be clinically inappropriate.</span></p><p><br></p><p><span style=""font-size: 9pt;"">ADALIMUMAB</span></p><p><b style=""font-size: 9pt;"">Renewal – (moderate to severely active ulcerative colitis; first biologic line)</b></p><p><span style=""font-size: 9pt;"">Only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is continuing to maintain remission and the benefit of continuing adalimumab outweighs the risks; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on adalimumab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Adalimumab to be administered at doses no greater than 40 mg every 14 days.</span></p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on the high health need of patients with moderate to severely active UC, balanced against the absence of evidence for superiority of adalimumab over infliximab in the first-line biologic treatment of UC, and uncertainty regarding barriers to infliximab use in District Health Boards (DHBs). The Committee noted that DHB infusion resources are under pressure and considered that this factor may contribute to access inequities.</p>', 'fs': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that <span style=""color: black;"">adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis (UC) </span>be funded with a low priority subject to the following Special Authority criteria:</p><p><span style=""font-size: 9pt;"">ADALIMUMAB</span></p><p><b style=""font-size: 9pt;"">Initial application – (moderate to severely active ulcerative colitis; first biologic line)</b></p><p><span style=""font-size: 9pt;"">Only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has histologically confirmed ulcerative colitis that is moderate to severely active; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) score is greater than or equal to 4; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and systemic corticosteroids; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Surgery (or further surgery) is considered to be clinically inappropriate.</span></p><p><br></p><p><span style=""font-size: 9pt;"">ADALIMUMAB</span></p><p><b style=""font-size: 9pt;"">Renewal – (moderate to severely active ulcerative colitis; first biologic line)</b></p><p><span style=""font-size: 9pt;"">Only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is continuing to maintain remission and the benefit of continuing adalimumab outweighs the risks; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on adalimumab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Adalimumab to be administered at doses no greater than 40 mg every 14 days.</span></p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on the high health need of patients with moderate to severely active UC, balanced against the absence of evidence for superiority of adalimumab over infliximab in the first-line biologic treatment of UC, and uncertainty regarding barriers to infliximab use in District Health Boards (DHBs). The Committee noted that DHB infusion resources are under pressure and considered that this factor may contribute to access inequities.</p>', 'change': None}, 'Published_Discussion': {'s': '<h2>Background</h2><p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the history of the supplier’s original application for adalimumab for the treatment of moderate to severely active UC that was received in September 2013:</p><p>3.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-11.pdf"" target=""_blank"">November 2013</a>, PTAC reviewed the application and recommended it for decline because of limited evidence for sustained clinical effectiveness, lack of long term safety data and high financial risk. PTAC requested further advice from the Gastrointestinal Subcommittee regarding a scoring scale for disease severity. </p><p>3.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2014-05-21.pdf"" target=""_blank"">May 2014</a>, the application was reviewed by the Gastrointestinal Subcommittee, which agreed with PTAC’s recommendation that the application be declined because of limited evidence for sustained clinical effectiveness, as well as a lack of long term safety data and high financial risk. The Gastrointestinal Subcommittee considered the additional information provided by the supplier was not sufficient to alter this recommendation.</p><p>3.3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">November 2014</a>, PTAC noted and accepted the Minutes of the Gastrointestinal Subcommittee meeting held on 21 May 2014.</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the history of the supplier’s resubmission for adalimumab for the treatment of moderate to severely active UC that was received in February 2017: </p><p>3.4.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2017-03.pdf"" target=""_blank"">March 2017</a>, the resubmission was reviewed by the Gastrointestinal Subcommittee, which recommended that adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis be declined. The Gastrointestinal Subcommittee noted that the efficacy of adalimumab and infliximab had not been directly compared, and considered adalimumab was unlikely to be more efficacious than infliximab.</p><p>3.4.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">November 2017</a>, PTAC reviewed the application for adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis and made no formal recommendation. PTAC considered that this is a large patient group and potentially high budget risk, and PTAC requested to review the evidence for the Subcommittee’s recommendation.</p><p>3.4.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"">May 2018</a>, PTAC reviewed the application for adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis and considered that the evidence shows that infliximab is likely to provide better health outcomes than adalimumab when used as a first-line biologic agent to treat ulcerative colitis. PTAC recommended that the application for adalimumab as a first biologic line treatment of ulcerative colitis be deferred until PHARMAC staff report back to PTAC on the availability of infliximab in each DHB.</p><h2>Discussion</h2><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposal is for the first-line biologic treatment with adalimumab for patients with moderate to severe ulcerative colitis (UC) who are refractory to and/or intolerant to prior systemic therapy, including a stable course of oral corticosteroids. </p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that adalimumab is proposed to be administered as a subcutaneous injection with an induction regimen of 160 mg initially then 80 mg at week 2, with subsequent administration at a dose of 40 mg every fortnight subject to sufficient response (determined by a decrease in Simple Crohn’s Colitis Activity Index [SCCAI] score of greater than or equal to 2 from initial assessment). </p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the SCCAI is a sum of scores from five questions assessed clinically, and that the Mayo score is a clinically useful but not specifically validated indicator of disease activity that uses clinical and endoscopic parameters. The Committee considered that the SCCAI is a validated, appropriate tool and noted that it is currently used in the Special Authority criteria for infliximab for severe UC. </p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier had proposed for adalimumab to be added as a later line of therapy in patients with moderate UC who have not responded to previous treatment with 5-ASAs, corticosteroids or immunomodulators; and in patients with severe UC who have not responded to corticosteroids with or without 5-ASAs and with or without immunomodulators.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that an average of 40% of patients with moderate to severely active disease could be contraindicated to, intolerant of, or unresponsive to conventional therapies. Members considered that the number of patients with severe UC in New Zealand could be less than that proposed by the supplier.</p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier’s 2013 application used placebo as a comparator, and the 2017 resubmission used infliximab as a comparator. The Committee considered that the appropriate, funded comparator is intravenous infliximab administered on a weight-based dosing schedule of 5 mg per kg initially, then at 2 and 6 weeks, then every 8 weeks. The Committee considered that it was unclear whether there is dose equivalence of adalimumab and infliximab at the dosages currently used for the treatment of UC.</p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that previous reviews of this application by PTAC had identified uncertainties regarding the optimal treatment of patients with moderate to severely active UC, and considered that the current body of evidence could not address all uncertainties. </p><p>3.11.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the optimal sequencing of treatments, dose and regimen (with or without therapeutic drug monitoring) and the most suitable location for administration eg. hospital outpatient setting or at home, was unclear. </p><p>3.11.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that in clinical practice, colectomy use is decreasing since the wider introduction of biologics. The use of biologic agents eg. adalimumab and infliximab for UC may delay surgery, although it is unclear what impact delaying surgery has on the number of patients who proceed to colectomy, or on the quality of life of patients with UC. </p><p>3.11.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is an increased risk of cancer with UC, and also an increased risk of cancer with long-term use of biologics, but considered it was unclear how delaying colectomy through longer use of biologics might change the risk of developing cancer due to increased exposure to the biologic. Members considered that the evidence suggests that treatment with biologics may convey some protective effect against cancer when used in other indications through earlier control of inflammation, but were unable to estimate the extent that such protection might translate and extend to the UC setting.</p><p>3.11.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that new pharmaceuticals, (eg. ustekinumab and vedolizumab) and biosimilar adalimumab products are becoming available for the treatment of UC and clinical trials investigating these are underway. </p><p>3.11.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that infliximab formulations for subcutaneous administration are becoming available, however, currently there is insufficient data to assess any differences in immunogenicity compared with intravenous administration.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there was no new evidence from randomised controlled trials that have directly compared adalimumab with infliximab in moderate to severely active UC. </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that there had been four indirect treatment comparisons carried out (<a href=""https://pubmed.ncbi.nlm.nih.gov/27220829-infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262-clinical-effectiveness-systematic-review-and-economic-model/?from_single_result=Infliximab%2C+adalimumab+and+golimumab+for+treating+moderately+to+severely+active+ulcerative+colitis+after+the+failure+of+conventional+therapy+%28including+a+review+of+TA140+and+TA262%29%3A+clinical+effectiveness+systematic+review+and+economic+model"" target=""_blank"">Archer et al. Health Technol Assess. 2016:20;1-326</a><span style=""color: black;"">, </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24842416-biological-agents-for-moderately-to-severely-active-ulcerative-colitis-a-systematic-review-and-network-meta-analysis/?from_term=Biological+Agents+for+Moderately+to+Severely+Active+Ulcerative+Colitis+A+Systematic+Review+and+Network+Meta-analysis&amp;from_pos=2"" target=""_blank"">Danese et al. Ann Intern Med. 2014:160;704-11</a><span style=""color: black;"">, </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24506179-systematic-review-with-network-meta-analysis-the-efficacy-of-anti-tumour-necrosis-factor-alpha-agents-for-the-treatment-of-ulcerative-colitis/?from_term=Systematic+review+with+network+meta-analysis%3A+the+efficacy+of+anti-tumour+necrosis+factor-alpha+agents+for+the+treatment+of+ulcerative+colitis&amp;from_pos=3"" target=""_blank"">Stidham et al. Aliment Pharmacol Ther. 2014:39;660-71</a><span style=""color: black;"">, and </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24491514-adalimumab-versus-infliximab-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-in-adult-patients-naive-to-anti-tnf-therapy-an-indirect-treatment-comparison-meta-analysis/?from_single_result=Adalimumab+versus+infliximab+for+the+treatment+of+moderate+to+severe+ulcerative+colitis+in+adult+patients+na%C3%AFve+to+anti-TNF+therapy%3A+An+indirect+treatment+comparison+meta-analysis"" target=""_blank"">Thorlund et al. J Crohns Colitis. 2014:8;571-81</a>). Members considered that most of this data suggests that infliximab may provide more benefit than adalimumab as induction therapy, and that these agents may provide roughly equivalent benefit in the maintenance setting (although two of the meta-analyses suggest that maintenance with adalimumab may provide more benefit than infliximab maintenance). Members considered that these indirect comparisons may suggest that clinical outcomes at one year after induction may be equivalent for adalimumab and infliximab.</p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the two years of claims data provided by PHARMAC for infliximab usage in the 20 District Health Boards (DHBs). </p><p>3.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that volume of infliximab used during the 2017 to 2019 financial years in each of the two available formulations (100 mg vial and 1 mg for ECP) was pooled into a total infliximab volume in milligrams per DHB per financial year for all indications. </p><p>3.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the claims data classifying infliximab use as specifically for funded UC indications (severe ulcerative colitis and severe fulminant ulcerative colitis) was only available for the 6-month period from March 2019 to August 2019, due to indication data collection only starting in early 2019.</p><p>3.14.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that these claims data show that infliximab is used to varying degrees at all 20 DHBs in New Zealand for the treatment of UC, however, the Committee was of the view that DHB infusion resources are at capacity levels and the variability in volume use may be due to access inequities. </p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee noted an absence of information about the barriers to infliximab use in each DHB and considered that PHARMAC could approach DHBs to request information about any barriers to infliximab use at each DHB. Members considered that potential barriers to infliximab treatment could include patient location and ability to travel (due to requirement for hospital infusion for treatment administration), DHB infusion resource capacity, access to specialist care under a gastroenterologist, evolving surgical and pharmaceutical treatment paradigms in gastroenterology, and clinician and patient preferences including time commitment for treatment. The Committee considered that barriers to access to infusion services should not prevent a positive Committee recommendation for funding, but acknowledged that barriers may exist and may result in or exacerbate access inequities. </span></p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee noted that a key benefit of adalimumab is convenience of administration. It was considered that if adalimumab were to be funded for </span>moderate to severely active <span style=""color: black;"">UC, some patients may receive infliximab for induction and then receive adalimumab for maintenance treatment.</span></p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there was no evidence of superiority of adalimumab over infliximab in the first-line biologic treatment of moderate to severely active UC. However, the Committee considered that <span style=""color: black;"">adalimumab is an acceptable alternative to infliximab</span> and that it should be<span style=""color: black;""> funded for first-line biologic treatment of moderate to severely active UC.</span></p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was not supportive of including the supplier-proposed additional prescribing options of “on the recommendation of a gastroenterologist or in accordance with a protocol or guideline that has been endorsed by the DHB Hospital” in the initial or renewal Special Authority criteria for adalimumab for the first-line biologic treatment of UC. The Committee noted that these proposed prescribing options would be inconsistent with the current, appropriate access criteria for adalimumab use in other indications.</p>', 'fs': '<h2>Background</h2><p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the history of the supplier’s original application for adalimumab for the treatment of moderate to severely active UC that was received in September 2013:</p><p>3.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-11.pdf"" target=""_blank"">November 2013</a>, PTAC reviewed the application and recommended it for decline because of limited evidence for sustained clinical effectiveness, lack of long term safety data and high financial risk. PTAC requested further advice from the Gastrointestinal Subcommittee regarding a scoring scale for disease severity. </p><p>3.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2014-05-21.pdf"" target=""_blank"">May 2014</a>, the application was reviewed by the Gastrointestinal Subcommittee, which agreed with PTAC’s recommendation that the application be declined because of limited evidence for sustained clinical effectiveness, as well as a lack of long term safety data and high financial risk. The Gastrointestinal Subcommittee considered the additional information provided by the supplier was not sufficient to alter this recommendation.</p><p>3.3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">November 2014</a>, PTAC noted and accepted the Minutes of the Gastrointestinal Subcommittee meeting held on 21 May 2014.</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the history of the supplier’s resubmission for adalimumab for the treatment of moderate to severely active UC that was received in February 2017: </p><p>3.4.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2017-03.pdf"" target=""_blank"">March 2017</a>, the resubmission was reviewed by the Gastrointestinal Subcommittee, which recommended that adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis be declined. The Gastrointestinal Subcommittee noted that the efficacy of adalimumab and infliximab had not been directly compared, and considered adalimumab was unlikely to be more efficacious than infliximab.</p><p>3.4.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">November 2017</a>, PTAC reviewed the application for adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis and made no formal recommendation. PTAC considered that this is a large patient group and potentially high budget risk, and PTAC requested to review the evidence for the Subcommittee’s recommendation.</p><p>3.4.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"">May 2018</a>, PTAC reviewed the application for adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis and considered that the evidence shows that infliximab is likely to provide better health outcomes than adalimumab when used as a first-line biologic agent to treat ulcerative colitis. PTAC recommended that the application for adalimumab as a first biologic line treatment of ulcerative colitis be deferred until PHARMAC staff report back to PTAC on the availability of infliximab in each DHB.</p><h2>Discussion</h2><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposal is for the first-line biologic treatment with adalimumab for patients with moderate to severe ulcerative colitis (UC) who are refractory to and/or intolerant to prior systemic therapy, including a stable course of oral corticosteroids. </p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that adalimumab is proposed to be administered as a subcutaneous injection with an induction regimen of 160 mg initially then 80 mg at week 2, with subsequent administration at a dose of 40 mg every fortnight subject to sufficient response (determined by a decrease in Simple Crohn’s Colitis Activity Index [SCCAI] score of greater than or equal to 2 from initial assessment). </p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the SCCAI is a sum of scores from five questions assessed clinically, and that the Mayo score is a clinically useful but not specifically validated indicator of disease activity that uses clinical and endoscopic parameters. The Committee considered that the SCCAI is a validated, appropriate tool and noted that it is currently used in the Special Authority criteria for infliximab for severe UC. </p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier had proposed for adalimumab to be added as a later line of therapy in patients with moderate UC who have not responded to previous treatment with 5-ASAs, corticosteroids or immunomodulators; and in patients with severe UC who have not responded to corticosteroids with or without 5-ASAs and with or without immunomodulators.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that an average of 40% of patients with moderate to severely active disease could be contraindicated to, intolerant of, or unresponsive to conventional therapies. Members considered that the number of patients with severe UC in New Zealand could be less than that proposed by the supplier.</p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier’s 2013 application used placebo as a comparator, and the 2017 resubmission used infliximab as a comparator. The Committee considered that the appropriate, funded comparator is intravenous infliximab administered on a weight-based dosing schedule of 5 mg per kg initially, then at 2 and 6 weeks, then every 8 weeks. The Committee considered that it was unclear whether there is dose equivalence of adalimumab and infliximab at the dosages currently used for the treatment of UC.</p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that previous reviews of this application by PTAC had identified uncertainties regarding the optimal treatment of patients with moderate to severely active UC, and considered that the current body of evidence could not address all uncertainties. </p><p>3.11.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the optimal sequencing of treatments, dose and regimen (with or without therapeutic drug monitoring) and the most suitable location for administration eg. hospital outpatient setting or at home, was unclear. </p><p>3.11.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that in clinical practice, colectomy use is decreasing since the wider introduction of biologics. The use of biologic agents eg. adalimumab and infliximab for UC may delay surgery, although it is unclear what impact delaying surgery has on the number of patients who proceed to colectomy, or on the quality of life of patients with UC. </p><p>3.11.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is an increased risk of cancer with UC, and also an increased risk of cancer with long-term use of biologics, but considered it was unclear how delaying colectomy through longer use of biologics might change the risk of developing cancer due to increased exposure to the biologic. Members considered that the evidence suggests that treatment with biologics may convey some protective effect against cancer when used in other indications through earlier control of inflammation, but were unable to estimate the extent that such protection might translate and extend to the UC setting.</p><p>3.11.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that new pharmaceuticals, (eg. ustekinumab and vedolizumab) and biosimilar adalimumab products are becoming available for the treatment of UC and clinical trials investigating these are underway. </p><p>3.11.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that infliximab formulations for subcutaneous administration are becoming available, however, currently there is insufficient data to assess any differences in immunogenicity compared with intravenous administration.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there was no new evidence from randomised controlled trials that have directly compared adalimumab with infliximab in moderate to severely active UC. </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that there had been four indirect treatment comparisons carried out (<a href=""https://pubmed.ncbi.nlm.nih.gov/27220829-infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262-clinical-effectiveness-systematic-review-and-economic-model/?from_single_result=Infliximab%2C+adalimumab+and+golimumab+for+treating+moderately+to+severely+active+ulcerative+colitis+after+the+failure+of+conventional+therapy+%28including+a+review+of+TA140+and+TA262%29%3A+clinical+effectiveness+systematic+review+and+economic+model"" target=""_blank"">Archer et al. Health Technol Assess. 2016:20;1-326</a><span style=""color: black;"">, </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24842416-biological-agents-for-moderately-to-severely-active-ulcerative-colitis-a-systematic-review-and-network-meta-analysis/?from_term=Biological+Agents+for+Moderately+to+Severely+Active+Ulcerative+Colitis+A+Systematic+Review+and+Network+Meta-analysis&amp;from_pos=2"" target=""_blank"">Danese et al. Ann Intern Med. 2014:160;704-11</a><span style=""color: black;"">, </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24506179-systematic-review-with-network-meta-analysis-the-efficacy-of-anti-tumour-necrosis-factor-alpha-agents-for-the-treatment-of-ulcerative-colitis/?from_term=Systematic+review+with+network+meta-analysis%3A+the+efficacy+of+anti-tumour+necrosis+factor-alpha+agents+for+the+treatment+of+ulcerative+colitis&amp;from_pos=3"" target=""_blank"">Stidham et al. Aliment Pharmacol Ther. 2014:39;660-71</a><span style=""color: black;"">, and </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24491514-adalimumab-versus-infliximab-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-in-adult-patients-naive-to-anti-tnf-therapy-an-indirect-treatment-comparison-meta-analysis/?from_single_result=Adalimumab+versus+infliximab+for+the+treatment+of+moderate+to+severe+ulcerative+colitis+in+adult+patients+na%C3%AFve+to+anti-TNF+therapy%3A+An+indirect+treatment+comparison+meta-analysis"" target=""_blank"">Thorlund et al. J Crohns Colitis. 2014:8;571-81</a>). Members considered that most of this data suggests that infliximab may provide more benefit than adalimumab as induction therapy, and that these agents may provide roughly equivalent benefit in the maintenance setting (although two of the meta-analyses suggest that maintenance with adalimumab may provide more benefit than infliximab maintenance). Members considered that these indirect comparisons may suggest that clinical outcomes at one year after induction may be equivalent for adalimumab and infliximab.</p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the two years of claims data provided by PHARMAC for infliximab usage in the 20 District Health Boards (DHBs). </p><p>3.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that volume of infliximab used during the 2017 to 2019 financial years in each of the two available formulations (100 mg vial and 1 mg for ECP) was pooled into a total infliximab volume in milligrams per DHB per financial year for all indications. </p><p>3.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the claims data classifying infliximab use as specifically for funded UC indications (severe ulcerative colitis and severe fulminant ulcerative colitis) was only available for the 6-month period from March 2019 to August 2019, due to indication data collection only starting in early 2019.</p><p>3.14.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that these claims data show that infliximab is used to varying degrees at all 20 DHBs in New Zealand for the treatment of UC, however, the Committee was of the view that DHB infusion resources are at capacity levels and the variability in volume use may be due to access inequities. </p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee noted an absence of information about the barriers to infliximab use in each DHB and considered that PHARMAC could approach DHBs to request information about any barriers to infliximab use at each DHB. Members considered that potential barriers to infliximab treatment could include patient location and ability to travel (due to requirement for hospital infusion for treatment administration), DHB infusion resource capacity, access to specialist care under a gastroenterologist, evolving surgical and pharmaceutical treatment paradigms in gastroenterology, and clinician and patient preferences including time commitment for treatment. The Committee considered that barriers to access to infusion services should not prevent a positive Committee recommendation for funding, but acknowledged that barriers may exist and may result in or exacerbate access inequities. </span></p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee noted that a key benefit of adalimumab is convenience of administration. It was considered that if adalimumab were to be funded for </span>moderate to severely active <span style=""color: black;"">UC, some patients may receive infliximab for induction and then receive adalimumab for maintenance treatment.</span></p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there was no evidence of superiority of adalimumab over infliximab in the first-line biologic treatment of moderate to severely active UC. However, the Committee considered that <span style=""color: black;"">adalimumab is an acceptable alternative to infliximab</span> and that it should be<span style=""color: black;""> funded for first-line biologic treatment of moderate to severely active UC.</span></p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was not supportive of including the supplier-proposed additional prescribing options of “on the recommendation of a gastroenterologist or in accordance with a protocol or guideline that has been endorsed by the DHB Hospital” in the initial or renewal Special Authority criteria for adalimumab for the first-line biologic treatment of UC. The Committee noted that these proposed prescribing options would be inconsistent with the current, appropriate access criteria for adalimumab use in other indications.</p>', 'change': None}, 'Published_Application': {'s': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed infliximab usage data provided by PHARMAC and noted the August 2013 and February 2017 applications from AbbVie for adalimumab <span style=""color: black;"">for the treatment of moderate to severely active ulcerative colitis (UC). </span></p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed infliximab usage data provided by PHARMAC and noted the August 2013 and February 2017 applications from AbbVie for adalimumab <span style=""color: black;"">for the treatment of moderate to severely active ulcerative colitis (UC). </span></p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/ptac-record-2019-11.pdf"" target=""_blank"">PTAC minutes</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/ptac-record-2019-11.pdf"" target=""_blank"">PTAC minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvRUAU'}, 'Id': 'a0P2P000005jLvRUAU', 'Event_Date__c': '2020-02-25', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/ptac-record-2019-11.pdf"" target=""_blank"">PTAC minutes</a></p>', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Feb 2020', 'Published_Recommendation__c': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that <span style=""color: black;"">adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis (UC) </span>be funded with a low priority subject to the following Special Authority criteria:</p><p><span style=""font-size: 9pt;"">ADALIMUMAB</span></p><p><b style=""font-size: 9pt;"">Initial application – (moderate to severely active ulcerative colitis; first biologic line)</b></p><p><span style=""font-size: 9pt;"">Only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has histologically confirmed ulcerative colitis that is moderate to severely active; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) score is greater than or equal to 4; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and systemic corticosteroids; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Surgery (or further surgery) is considered to be clinically inappropriate.</span></p><p><br></p><p><span style=""font-size: 9pt;"">ADALIMUMAB</span></p><p><b style=""font-size: 9pt;"">Renewal – (moderate to severely active ulcerative colitis; first biologic line)</b></p><p><span style=""font-size: 9pt;"">Only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is continuing to maintain remission and the benefit of continuing adalimumab outweighs the risks; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on adalimumab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Adalimumab to be administered at doses no greater than 40 mg every 14 days.</span></p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on the high health need of patients with moderate to severely active UC, balanced against the absence of evidence for superiority of adalimumab over infliximab in the first-line biologic treatment of UC, and uncertainty regarding barriers to infliximab use in District Health Boards (DHBs). The Committee noted that DHB infusion resources are under pressure and considered that this factor may contribute to access inequities.</p>', 'Published_Application__c': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed infliximab usage data provided by PHARMAC and noted the August 2013 and February 2017 applications from AbbVie for adalimumab <span style=""color: black;"">for the treatment of moderate to severely active ulcerative colitis (UC). </span></p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h2>Background</h2><p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the history of the supplier’s original application for adalimumab for the treatment of moderate to severely active UC that was received in September 2013:</p><p>3.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-11.pdf"" target=""_blank"">November 2013</a>, PTAC reviewed the application and recommended it for decline because of limited evidence for sustained clinical effectiveness, lack of long term safety data and high financial risk. PTAC requested further advice from the Gastrointestinal Subcommittee regarding a scoring scale for disease severity. </p><p>3.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2014-05-21.pdf"" target=""_blank"">May 2014</a>, the application was reviewed by the Gastrointestinal Subcommittee, which agreed with PTAC’s recommendation that the application be declined because of limited evidence for sustained clinical effectiveness, as well as a lack of long term safety data and high financial risk. The Gastrointestinal Subcommittee considered the additional information provided by the supplier was not sufficient to alter this recommendation.</p><p>3.3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-11.pdf"" target=""_blank"">November 2014</a>, PTAC noted and accepted the Minutes of the Gastrointestinal Subcommittee meeting held on 21 May 2014.</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the history of the supplier’s resubmission for adalimumab for the treatment of moderate to severely active UC that was received in February 2017: </p><p>3.4.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-gastrointestinal-subcommittee-minutes-2017-03.pdf"" target=""_blank"">March 2017</a>, the resubmission was reviewed by the Gastrointestinal Subcommittee, which recommended that adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis be declined. The Gastrointestinal Subcommittee noted that the efficacy of adalimumab and infliximab had not been directly compared, and considered adalimumab was unlikely to be more efficacious than infliximab.</p><p>3.4.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-11.pdf"" target=""_blank"">November 2017</a>, PTAC reviewed the application for adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis and made no formal recommendation. PTAC considered that this is a large patient group and potentially high budget risk, and PTAC requested to review the evidence for the Subcommittee’s recommendation.</p><p>3.4.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"">May 2018</a>, PTAC reviewed the application for adalimumab for the first-line biologic treatment of moderate to severely active ulcerative colitis and considered that the evidence shows that infliximab is likely to provide better health outcomes than adalimumab when used as a first-line biologic agent to treat ulcerative colitis. PTAC recommended that the application for adalimumab as a first biologic line treatment of ulcerative colitis be deferred until PHARMAC staff report back to PTAC on the availability of infliximab in each DHB.</p><h2>Discussion</h2><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposal is for the first-line biologic treatment with adalimumab for patients with moderate to severe ulcerative colitis (UC) who are refractory to and/or intolerant to prior systemic therapy, including a stable course of oral corticosteroids. </p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that adalimumab is proposed to be administered as a subcutaneous injection with an induction regimen of 160 mg initially then 80 mg at week 2, with subsequent administration at a dose of 40 mg every fortnight subject to sufficient response (determined by a decrease in Simple Crohn’s Colitis Activity Index [SCCAI] score of greater than or equal to 2 from initial assessment). </p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the SCCAI is a sum of scores from five questions assessed clinically, and that the Mayo score is a clinically useful but not specifically validated indicator of disease activity that uses clinical and endoscopic parameters. The Committee considered that the SCCAI is a validated, appropriate tool and noted that it is currently used in the Special Authority criteria for infliximab for severe UC. </p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier had proposed for adalimumab to be added as a later line of therapy in patients with moderate UC who have not responded to previous treatment with 5-ASAs, corticosteroids or immunomodulators; and in patients with severe UC who have not responded to corticosteroids with or without 5-ASAs and with or without immunomodulators.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that an average of 40% of patients with moderate to severely active disease could be contraindicated to, intolerant of, or unresponsive to conventional therapies. Members considered that the number of patients with severe UC in New Zealand could be less than that proposed by the supplier.</p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier’s 2013 application used placebo as a comparator, and the 2017 resubmission used infliximab as a comparator. The Committee considered that the appropriate, funded comparator is intravenous infliximab administered on a weight-based dosing schedule of 5 mg per kg initially, then at 2 and 6 weeks, then every 8 weeks. The Committee considered that it was unclear whether there is dose equivalence of adalimumab and infliximab at the dosages currently used for the treatment of UC.</p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that previous reviews of this application by PTAC had identified uncertainties regarding the optimal treatment of patients with moderate to severely active UC, and considered that the current body of evidence could not address all uncertainties. </p><p>3.11.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the optimal sequencing of treatments, dose and regimen (with or without therapeutic drug monitoring) and the most suitable location for administration eg. hospital outpatient setting or at home, was unclear. </p><p>3.11.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that in clinical practice, colectomy use is decreasing since the wider introduction of biologics. The use of biologic agents eg. adalimumab and infliximab for UC may delay surgery, although it is unclear what impact delaying surgery has on the number of patients who proceed to colectomy, or on the quality of life of patients with UC. </p><p>3.11.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is an increased risk of cancer with UC, and also an increased risk of cancer with long-term use of biologics, but considered it was unclear how delaying colectomy through longer use of biologics might change the risk of developing cancer due to increased exposure to the biologic. Members considered that the evidence suggests that treatment with biologics may convey some protective effect against cancer when used in other indications through earlier control of inflammation, but were unable to estimate the extent that such protection might translate and extend to the UC setting.</p><p>3.11.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that new pharmaceuticals, (eg. ustekinumab and vedolizumab) and biosimilar adalimumab products are becoming available for the treatment of UC and clinical trials investigating these are underway. </p><p>3.11.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that infliximab formulations for subcutaneous administration are becoming available, however, currently there is insufficient data to assess any differences in immunogenicity compared with intravenous administration.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there was no new evidence from randomised controlled trials that have directly compared adalimumab with infliximab in moderate to severely active UC. </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that there had been four indirect treatment comparisons carried out (<a href=""https://pubmed.ncbi.nlm.nih.gov/27220829-infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262-clinical-effectiveness-systematic-review-and-economic-model/?from_single_result=Infliximab%2C+adalimumab+and+golimumab+for+treating+moderately+to+severely+active+ulcerative+colitis+after+the+failure+of+conventional+therapy+%28including+a+review+of+TA140+and+TA262%29%3A+clinical+effectiveness+systematic+review+and+economic+model"" target=""_blank"">Archer et al. Health Technol Assess. 2016:20;1-326</a><span style=""color: black;"">, </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24842416-biological-agents-for-moderately-to-severely-active-ulcerative-colitis-a-systematic-review-and-network-meta-analysis/?from_term=Biological+Agents+for+Moderately+to+Severely+Active+Ulcerative+Colitis+A+Systematic+Review+and+Network+Meta-analysis&amp;from_pos=2"" target=""_blank"">Danese et al. Ann Intern Med. 2014:160;704-11</a><span style=""color: black;"">, </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24506179-systematic-review-with-network-meta-analysis-the-efficacy-of-anti-tumour-necrosis-factor-alpha-agents-for-the-treatment-of-ulcerative-colitis/?from_term=Systematic+review+with+network+meta-analysis%3A+the+efficacy+of+anti-tumour+necrosis+factor-alpha+agents+for+the+treatment+of+ulcerative+colitis&amp;from_pos=3"" target=""_blank"">Stidham et al. Aliment Pharmacol Ther. 2014:39;660-71</a><span style=""color: black;"">, and </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24491514-adalimumab-versus-infliximab-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-in-adult-patients-naive-to-anti-tnf-therapy-an-indirect-treatment-comparison-meta-analysis/?from_single_result=Adalimumab+versus+infliximab+for+the+treatment+of+moderate+to+severe+ulcerative+colitis+in+adult+patients+na%C3%AFve+to+anti-TNF+therapy%3A+An+indirect+treatment+comparison+meta-analysis"" target=""_blank"">Thorlund et al. J Crohns Colitis. 2014:8;571-81</a>). Members considered that most of this data suggests that infliximab may provide more benefit than adalimumab as induction therapy, and that these agents may provide roughly equivalent benefit in the maintenance setting (although two of the meta-analyses suggest that maintenance with adalimumab may provide more benefit than infliximab maintenance). Members considered that these indirect comparisons may suggest that clinical outcomes at one year after induction may be equivalent for adalimumab and infliximab.</p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the two years of claims data provided by PHARMAC for infliximab usage in the 20 District Health Boards (DHBs). </p><p>3.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that volume of infliximab used during the 2017 to 2019 financial years in each of the two available formulations (100 mg vial and 1 mg for ECP) was pooled into a total infliximab volume in milligrams per DHB per financial year for all indications. </p><p>3.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the claims data classifying infliximab use as specifically for funded UC indications (severe ulcerative colitis and severe fulminant ulcerative colitis) was only available for the 6-month period from March 2019 to August 2019, due to indication data collection only starting in early 2019.</p><p>3.14.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that these claims data show that infliximab is used to varying degrees at all 20 DHBs in New Zealand for the treatment of UC, however, the Committee was of the view that DHB infusion resources are at capacity levels and the variability in volume use may be due to access inequities. </p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee noted an absence of information about the barriers to infliximab use in each DHB and considered that PHARMAC could approach DHBs to request information about any barriers to infliximab use at each DHB. Members considered that potential barriers to infliximab treatment could include patient location and ability to travel (due to requirement for hospital infusion for treatment administration), DHB infusion resource capacity, access to specialist care under a gastroenterologist, evolving surgical and pharmaceutical treatment paradigms in gastroenterology, and clinician and patient preferences including time commitment for treatment. The Committee considered that barriers to access to infusion services should not prevent a positive Committee recommendation for funding, but acknowledged that barriers may exist and may result in or exacerbate access inequities. </span></p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Committee noted that a key benefit of adalimumab is convenience of administration. It was considered that if adalimumab were to be funded for </span>moderate to severely active <span style=""color: black;"">UC, some patients may receive infliximab for induction and then receive adalimumab for maintenance treatment.</span></p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there was no evidence of superiority of adalimumab over infliximab in the first-line biologic treatment of moderate to severely active UC. However, the Committee considered that <span style=""color: black;"">adalimumab is an acceptable alternative to infliximab</span> and that it should be<span style=""color: black;""> funded for first-line biologic treatment of moderate to severely active UC.</span></p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee was not supportive of including the supplier-proposed additional prescribing options of “on the recommendation of a gastroenterologist or in accordance with a protocol or guideline that has been endorsed by the DHB Hospital” in the initial or renewal Special Authority criteria for adalimumab for the first-line biologic treatment of UC. The Committee noted that these proposed prescribing options would be inconsistent with the current, appropriate access criteria for adalimumab use in other indications.</p>', 'Status_History__c': 'a132P000000BV3nQAG'}, 'change': None}]",Nov 2013,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvFUAU'}, 'Id': 'a0P2P000005jLvFUAU', 'Event_Date__c': '2013-11-19', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqXUQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvSUAU'}, 'Id': 'a0P2P000005jLvSUAU', 'Event_Date__c': '2020-02-25', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BV3zQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvUUAU'}, 'Id': 'a0P2P000005jLvUUAU', 'Event_Date__c': '2021-02-22', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2021', 'Status_History__c': 'a132P000000CclKQAS'}, 'change': None}]",Nov 2013,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2014', 'fs': 'Mar 2014', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvGUAU'}, 'Id': 'a0P2P000005jLvGUAU', 'Event_Date__c': '2014-03-20', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2014', 'Status_History__c': 'a132P000000AqcvQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2015', 'fs': 'Mar 2015', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvKUAU'}, 'Id': 'a0P2P000005jLvKUAU', 'Event_Date__c': '2015-03-30', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2015', 'Status_History__c': 'a132P000000AqtoQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2017', 'fs': 'Feb 2017', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvLUAU'}, 'Id': 'a0P2P000005jLvLUAU', 'Event_Date__c': '2017-02-01', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Feb 2017', 'Status_History__c': 'a132P000000ArFDQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvTUAU'}, 'Id': 'a0P2P000005jLvTUAU', 'Event_Date__c': '2020-06-23', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000BtQzQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvVUAU'}, 'Id': 'a0P2P000005jLvVUAU', 'Event_Date__c': '2021-03-11', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CfrVQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvWUAU'}, 'Id': 'a0P2P000005jLvWUAU', 'Event_Date__c': '2021-06-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CuoYQAS'}, 'change': None}]",Mar 2014,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-08-26-proposal-to-widen-access-to-adalimumab-and-award-principal-supply/', 'fs': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-08-26-proposal-to-widen-access-to-adalimumab-and-award-principal-supply/', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2021', 'fs': 'Sep 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvXUAU'}, 'Id': 'a0P2P000005jLvXUAU', 'Event_Date__c': '2021-09-01', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Summary__c': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-08-26-proposal-to-widen-access-to-adalimumab-and-award-principal-supply/', 'Formatted_Date__c': 'Sep 2021', 'Status_History__c': 'a132P000000D8O2QAK'}, 'change': None}]",Sep 2021,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2021', 'fs': 'Oct 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvYUAU'}, 'Id': 'a0P2P000005jLvYUAU', 'Event_Date__c': '2021-10-28', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Oct 2021', 'Status_History__c': 'a132P000000DHJIQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2021', 'fs': 'Oct 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvZUAU'}, 'Id': 'a0P2P000005jLvZUAU', 'Event_Date__c': '2021-10-28', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Oct 2021', 'Status_History__c': 'a132P000000DHJNQA4'}, 'change': None}]",Oct 2021,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2021', 'fs': 'Nov 2021', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvaUAE'}, 'Id': 'a0P2P000005jLvaUAE', 'Event_Date__c': '2021-11-23', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Formatted_Date__c': 'Nov 2021', 'Status_History__c': 'a132P000000DMhLQAW'}, 'change': None}, {'Summary': {'s': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-11-17-decision-to-widen-access-to-adalimumab-and-award-principal-supply/', 'fs': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-11-17-decision-to-widen-access-to-adalimumab-and-award-principal-supply/', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2021', 'fs': 'Nov 2021', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005jLvbUAE'}, 'Id': 'a0P2P000005jLvbUAE', 'Event_Date__c': '2021-11-23', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-11-17-decision-to-widen-access-to-adalimumab-and-award-principal-supply/', 'Formatted_Date__c': 'Nov 2021', 'Status_History__c': 'a132P000000DMhQQAW'}, 'change': None}]",Nov 2021,False,True
